Dyadic International

Dyadic International

Yahoo Finance • 3 days ago

Linamar Corp (LIMAF) (Q2 2026) Earnings Call Highlights: Record Sales and Strategic Wins Amid ...

This article first appeared on GuruFocus. Revenue: Record sales of $3.1 billion, up 18.8% year-over-year. Normalized Net Earnings: $183 million, or 5.8% of sales, up 8.7% from the prior year. Normalized EPS: $3.08, up 9.6% year-over-year.... Full story

Yahoo Finance • 4 days ago

Dyadic International GAAP EPS of -$0.06 misses by $0.03, revenue of $0.96M misses by $0.67M

* Dyadic International press release [https://seekingalpha.com/pr/20616496-dyadic-announces-second-quarter-2026-financial-results-accelerating-commercialization] (DYAI [https://seekingalpha.com/symbol/DYAI]): Q2 GAAP EPS of -$0.06 misses... Full story

Yahoo Finance • 20 days ago

Dyadic Regains Compliance With Nasdaq Listing Rules

(RTTNews) - Dyadic International Inc. (DYAI), doing business as Dyadic Applied BioSolutions, a biotechnology company, on Friday reported regaining compliance with the Listing Rules of The Nasdaq Stock Exchange LLC. The company previously... Full story

Yahoo Finance • 23 days ago

Dyadic Announces Continued Listing on the Nasdaq Capital Market

Dyadic International, Inc. JUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein s... Full story

Yahoo Finance • last month

Top Biotech Gainers: NXTC Soars On Merger Deal, BMGL Moves Past Nasdaq Woes, OTLK Awaits FDA Verdict

(RTTNews) - Today's top gainers in the biotech space include NextCure, ahead of its planned merger with a private company that will create a newly branded public entity; Basel Medical, which recently regained Nasdaq compliance; and Outlook... Full story

Yahoo Finance • last month

Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

JUPITER, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalab... Full story

Yahoo Finance • 2 months ago

Dyadic Expands IP Protection and Business Development Activities in Japan

JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalab... Full story

Yahoo Finance • 2 months ago

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

JUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions (“Dyadic” or the “Company”), a biotechnology company focused on the development and commercialization of scalab... Full story

Yahoo Finance • 2 months ago

Dyadic (DYAI) Q1 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, March 25, 2026 at 5 p.m. ET CALL PARTICIPANTS President and Chief Operating Officer — Joseph Hazelton Chief Executive Officer — Mark Emalfarb Chief Financial Officer — Ping Rawson Need a... Full story

Yahoo Finance • 3 months ago

Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference

JUPITER, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered,... Full story

Yahoo Finance • 3 months ago

Dyadic outlines cash runway into Q2 2027 while targeting mid-2026 alpha-lactalbumin sampling

Earnings Call Insights: Dyadic International (DYAI) Q1 2026 MANAGEMENT VIEW * “Over the last several years, we have worked to transform Dyadic from a platform technology company into a commercially focused biotechnology company capable... Full story

Yahoo Finance • 3 months ago

Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress

Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industryCommercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platfo... Full story

Yahoo Finance • 5 months ago

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with Dyadic eligible to receive a share of profits from product salesExpanded strategic collaboration with Fer... Full story

Yahoo Finance • 5 months ago

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are... Full story

Yahoo Finance • 5 months ago

Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable product... Full story

Yahoo Finance • 9 months ago

Dyadic outlines new commercial focus as first bulk protein sales and Asia expansion accelerate growth trajectory

Earnings Call Insights: Dyadic International, Inc. (DYAI) Q3 2025 MANAGEMENT VIEW * President & COO Joseph Hazelton highlighted a pivotal shift, stating Dyadic is now operating as a “commercially focused biotechnology company with a gr... Full story

Yahoo Finance • 9 months ago

Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress

CompletedstrategicpivotfromR&Dfocustocommercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relationsAdvancedmultiplerecombinantproteinprogramstowardcommercia... Full story

Yahoo Finance • 10 months ago

Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025

JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable producti... Full story

Yahoo Finance • last year

Dyadic anticipates $500,000 milestone and targets commercialization ramp through 2026

Earnings Call Insights: Dyadic International, Inc. (DYAI) Q2 2025 MANAGEMENT VIEW * Joseph P. Hazelton, President & COO, stated Dyadic has shifted from a platform-focused R&D company to a commercially-driven biotechnology business, emp... Full story

Yahoo Finance • last year

Earnings call transcript: Dyadic Q2 2025 sees revenue growth, stock dips

Dyadic International Inc. (DYAI) reported its financial results for the second quarter of 2025, showing significant revenue growth but a continued net loss. The company posted an EPS of -0.06, matching forecasts, while revenue slightly exc... Full story